| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/25/2004 | CN1477966A Shark meat extract |
| 02/25/2004 | CN1477965A Pharmaceutical product for treatment and diagnosis of tumors and method for preparation of liqid free fraction of blood plasma |
| 02/25/2004 | CN1477964A Treatment of neoplasms with viruses |
| 02/25/2004 | CN1477960A EPA receptor inhibitors to treat rheumatoid arthritis |
| 02/25/2004 | CN1477129A Recombinant vascular endothelial growth factor-diphtherin fusion protein, its preparation and application |
| 02/25/2004 | CN1477103A Chird sugarapple lactone compound modified by ether bond, its synthesis method and application |
| 02/25/2004 | CN1476900A Adjustable controllable tumor eiving vacine and its preparation method |
| 02/25/2004 | CN1476899A Multi-medicine medicine-resistant RNA interference medicine for resisting tumor |
| 02/25/2004 | CN1476896A Production method of nano medicine carrier |
| 02/25/2004 | CN1476886A Health-care tea for resisting cancer and resisting SARS |
| 02/25/2004 | CN1476850A Feikang capsule |
| 02/25/2004 | CN1476830A Tea-polyphenol soft capsule and its preparation process |
| 02/25/2004 | CN1476829A Application of toosendanin as anti-tumor medicine |
| 02/25/2004 | CN1139593C 3 alpha-bromoepipodophyllotoxin, its position-4 substituted derivative and preparing process thereof |
| 02/25/2004 | CN1139592C Camptothecin derivatives its preparing and use and midbody |
| 02/25/2004 | CN1139584C Heterocyclic compounds, method for preparing and medicine composition containing same |
| 02/25/2004 | CN1139570C Inhibition of matrix metalloproteases by acetylene-containing compound |
| 02/25/2004 | CN1139387C Epimedium polysaccharide and its preparing method, and its application in preparing medicine for raising body's immunity |
| 02/25/2004 | CN1139384C Therapeutic composition based on flavonoids for use in treatment of tumours with cytotoxic agents |
| 02/25/2004 | CN1139383C Therapeutic composition containing isoflavonoids for process in treatment of tumours with cytotoxic agents |
| 02/24/2004 | US6696567 Pyrrolo[2,3-d]pyrimidine compounds |
| 02/24/2004 | US6696495 Treatment of disorders secondary to organic impairments |
| 02/24/2004 | US6696482 Formulations for hydrophobic pharmaceutical agents |
| 02/24/2004 | US6696478 Compound targeted to protein kinase c enzyme |
| 02/24/2004 | US6696470 Pyridylthiophene compounds |
| 02/24/2004 | US6696463 3-heteroarylidenyl-2-azaindolinones active as protein tyrosine kinase inhibitors |
| 02/24/2004 | US6696458 Having x-ray powder diffraction pattern with lines at degrees 2 theta values 6.7, 12.5, 14.0 and 23.9 for cu k alpha radiation of wavelength 1.5406 angstrom |
| 02/24/2004 | US6696455 Nitrogen compounds such as 6-chloro-2-methyl-4-oxo-pyrido (3,2-d)pyrimidine used as anticarcinogenic agents and/or for prophylaxis of infections caused by pneumocystis or toxoplasma |
| 02/24/2004 | US6696452 Glycogen synthase kinase-3 and aurora-2 a serine/threonine protein kinase inhibitors; antidiabetic and anticancer agents and alzheimer's disease treatments |
| 02/24/2004 | US6696449 Control degradation of conencting tissue; cardiovascular disorders |
| 02/24/2004 | US6696446 Benzoylpyridazines, their preparation and use |
| 02/24/2004 | US6696437 Polymerase inhibitors comprising heterocyclic amides such as 2-pyridin-2-ylbenzimidazole-4-carboxamide, used for prophylaxis of neurodegenerative disorders, damage to hearts or brains, and as anticarcinogenic agents |
| 02/24/2004 | US6696434 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
| 02/24/2004 | US6696431 Administering compounds such as 20(s)-1-alpha,25-dihydroxy-2-methylene-26,27-dihomo-19-norvitamin d3, for the prophylaxis of skin disorders such as psoriasis |
| 02/24/2004 | US6696428 Use of dopamine receptor antagonists in palliative tumor therapy |
| 02/24/2004 | US6696427 Use of bisphosphonates for the prevention and treatment of infectious processes |
| 02/24/2004 | US6696416 Synthetic multimer proteins comprising octapeptides used for suppression metastasis or tumors; anticarcinogenic agents |
| 02/24/2004 | US6696408 Administering glycosylated polypeptides as antiepileptics and anticonvulsants or for prophylaxis of psychological disorders |
| 02/24/2004 | US6696276 Vasopermeability-enhancing conjugates |
| 02/24/2004 | US6696263 PCNA associated cell cycle proteins, compositions and methods of use |
| 02/24/2004 | US6696079 Delivery and activation through liposome incorporation of diaminocyclohexane platinum(II) complexes |
| 02/24/2004 | CA2219081C Angiostatin fragments and aggregate angiostatin and methods of use |
| 02/24/2004 | CA2199399C .beta.,.beta.'-dihydroxy meso-substituted chlorins, isobacteriochlorins, bacteriochlorins, and methods for making the same from .beta.,.beta.'-unsubstituted tetrapyrrolic macrocyles |
| 02/24/2004 | CA2150944C New taxoids; process for preparing the same and pharmaceutical compositions containing them |
| 02/24/2004 | CA2132213C Specific detection of cell surface receptor leukocyte adhesion molecule-1 |
| 02/19/2004 | WO2004015109A1 Human acid sensing ion channel 2b (hasic2b), process for producing the same, and its use |
| 02/19/2004 | WO2004015106A1 Methods to reprogram splice site selection in pre-messenger rnas |
| 02/19/2004 | WO2004015072A2 Mrbs as modifiers of the rb pathway and methods of use |
| 02/19/2004 | WO2004015062A2 Methods and compositions relating to gene silencing |
| 02/19/2004 | WO2004014957A1 Novel immunogenic lipopeptides comprising t-helper and cytotoxic t lymphocyte (ctl) epitopes |
| 02/19/2004 | WO2004014946A1 A novel homo protein with cancer suppressing function and its coding sequence |
| 02/19/2004 | WO2004014935A1 Progesterone receptor modulators having an increased antigonadotropic activity for use in female fertility testing and hormone replacement therapy |
| 02/19/2004 | WO2004014928A2 Novel difluorinated gem compounds, preparation methods thereof and applications of same |
| 02/19/2004 | WO2004014922A1 3-(carbonyl) 1h-indazole compounds as cyclin dependent kinases (cdk) inhibitors |
| 02/19/2004 | WO2004014920A1 Bicyclic heteroaromatic compounds as kinase inhibitors |
| 02/19/2004 | WO2004014919A1 Epothilone derivatives |
| 02/19/2004 | WO2004014918A1 Nitro and amino substituted topoisomerase agents |
| 02/19/2004 | WO2004014917A2 Antitumoral analogs of lamellarins |
| 02/19/2004 | WO2004014911A1 Phosphodiesterase 4 inhibitors |
| 02/19/2004 | WO2004014910A1 Dihydropyrazolopyridine compounds |
| 02/19/2004 | WO2004014908A1 Heterobicylcic metalloproteinase inhibitors |
| 02/19/2004 | WO2004014906A2 Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents |
| 02/19/2004 | WO2004014905A1 Substituted benzimidazole compounds |
| 02/19/2004 | WO2004014904A1 Antiproliferative 2-(heteroaryl)-aminothiazole compounds, pharmaceutical compositions and methods for their use |
| 02/19/2004 | WO2004014903A1 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| 02/19/2004 | WO2004014900A1 Benzimidazoles and benzothiazoles as inhibitors of map kinase |
| 02/19/2004 | WO2004014899A1 Thiophene compounds |
| 02/19/2004 | WO2004014876A1 Urea derivatives as kinase inhibitors |
| 02/19/2004 | WO2004014864A1 1h-indazole-3-carboxamide compounds as cyclin dependent kinases (cdk) inhibitors |
| 02/19/2004 | WO2004014862A1 Nitro and amino substituted heterocycles as topoisomerase i targeting agents |
| 02/19/2004 | WO2004014859A2 Process for preparing quinolin antibiotic intermediates |
| 02/19/2004 | WO2004014851A2 Tyrosine kinase inhibitors |
| 02/19/2004 | WO2004014825A1 Cannabinoid receptor ligands |
| 02/19/2004 | WO2004014433A1 Inhibition of proliferation and infiltration of brain tumor cells caused by expression of ampa-type glutamate receptor subunit |
| 02/19/2004 | WO2004014430A1 Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
| 02/19/2004 | WO2004014426A1 Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer |
| 02/19/2004 | WO2004014421A1 Use of antibodies against a tumor-associated antigen |
| 02/19/2004 | WO2004014415A1 Growth hormone releasing peptides |
| 02/19/2004 | WO2004014401A1 Metal cluster nano-compounds for treating tumor diseases |
| 02/19/2004 | WO2004014386A1 Therapeutic combinations of erb b kinase inhibitors and antineoplastic therapies |
| 02/19/2004 | WO2004014383A1 Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer |
| 02/19/2004 | WO2004014374A1 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 02/19/2004 | WO2004014352A2 Methods for treating carbonic anhydrase mediated disorders |
| 02/19/2004 | WO2004014319A2 Screening strategy for anticancer drugs |
| 02/19/2004 | WO2004014314A2 Methods and compositions concerning poxviruses and cancer |
| 02/19/2004 | WO2004014304A2 Electrospun amorphous pharmaceutical compositions |
| 02/19/2004 | WO2004014301A2 PSMCs AS MODIFIERS OF THE RB PATHWAY AND METHODS OF USE |
| 02/19/2004 | WO2004014293A2 Combination of anti-muscarinic agents and non-glucocorticoid steroids |
| 02/19/2004 | WO2004014222A2 Diagnosis and treatment of tuberous sclerosis |
| 02/19/2004 | WO2004014150A1 Denatured carob flour (dcf) with a low content of soluble tannins and sugars, meant for human consumption and process to obtain it |
| 02/19/2004 | WO2004007481A3 Substituted amine derivatives and methods of use in the treatment of angiogenesis relates disorders |
| 02/19/2004 | WO2004007478A3 Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, process for their preparation and their pharmaceutical use |
| 02/19/2004 | WO2004007430A3 Benzamide or phenylacetamide derivatives useful as thyroid receptor ligands |
| 02/19/2004 | WO2003104473A3 Galactosyl isomalt, method for production and use thereof |
| 02/19/2004 | WO2003103706A3 Immunogenic compositions comprising a xenogenic prostate protein p501s |
| 02/19/2004 | WO2003102584A3 Semaphorin-like proteins and methods of using same |
| 02/19/2004 | WO2003101995A3 Camptothecins with a modified lactone ring |
| 02/19/2004 | WO2003100060A3 Muc-1 antigen with reduced number of vntr repeat units |
| 02/19/2004 | WO2003099193A3 Vaccines |
| 02/19/2004 | WO2003089423A3 Novel flavanoids and chalcones as chemotherapeutic, chemopreventive, and antiangiogenic agents |